This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
This pharmaphorum webinar, held in association with Savana, will take place on Thursday 22 April from 16:00-17:00 BST / 17:00-18:00 CET / 10:00-11:00 EST and hear from presenters at BREATHE – the health dataresearch hub for respiratory health, Salford Royal NHS Foundation Trust and Savana.
Real-world evidence (RWE) is emerging as an important area of research to reveal, in real time, new insights and innovations in medicine. The webinar explored the potential of the technology to process the vast amount of data languishing untapped in EHRs, while ensuring that patient data privacy and safety is maintained at all times.
Countries like Estonia and Finland have taken on a completely digitised approach to their health services , integrating EHR data to efficiently prescribe medications and improve treatment strategies. Darwin is part of a package of projects and initiatives to transform to data-driven medicines regulation.”.
If you hadn’t already noticed, the clinicalresearch enterprise has well and truly entered the era of “bigdata,” artificial intelligence (AI), and machine learning. Undoubtedly, the expectations for precision medicine are high,” Olsen adds.
Landry is a professor of medicine and epidemiology at Oxford Population Health and deputy director of the University of Oxford’s BigData Institute. ElZarrad is the director of the Office of Medical Policy in the FDA’s Center for Drug Evaluation and Research. Join the online meeting.
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Just in time to help recognize Pride Month , ACRP’s ClinicalResearcher journal is pleased to share the first details from the lead peer-reviewed article on “Improving Cardiovascular Research for Transgender and Gender Diverse Populations” from a trio of WCG IRB expert contributors to the new issue going online today (June 13).
Attendees will learn more about how an SCA was used at the design and execution phases in a recent study of new treatments for relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL) and will also receive an eBook ‘How to harness the potential of AI and real-world data for clinicalresearch’. About the panel.
Through these collaborations, advanced technologies tied to AI and bigdata are being employed to develop personalized and targeted medicines, ultimately leading to more effective treatments for diseases like cancer and immune deficiencies,” Lyons notes.
It was a time when “the potential for systematic understanding of complex biology was palpable”, a fascinating terrain wherein the “first bacterial genomes were being sequenced”, when microarray technology was in the early stages of being invented, and ‘genomics’ and ‘bigdata’ certainly weren’t on the tips of people’s tongues.
Currently, the EMA’s human medicines committee (CHMP) carries out its assessment of new medicines or post-marketing label extensions using data from clinical summaries and information reported in clinical study reports (CSRs).
For the past ten years we’ve seen a steady acceptance of the need for patient engagement practises to become routine and integrated into all systems of healthcare and the creation of new medicines and devices. Patients are beginning to expect the providers of their medicines to help them with their condition and the impact on their lives.
And this is where modern technologies and data-driven medical informatics can really bridge the gaps in rare disease research,” said Dr Joanne Hackett, head of Genomic and Precision Medicine at IQVIA, during a recent pharmaphorum webinar. Thus, she belongs to the Center for Medical Informatics at the University Medicine Dresden.
As we explore Genmab’s strategic vision, technological advancements and the next frontier in antibody research, we gain insights into the future of medicine — a future where Genmab’s cutting-edge therapies are poised to transform patient care and meet the complex challenges of the next generation of healthcare.
a leader in precision medicine and artificial intelligence (AI)-enabled patient-centric oncology clinical trial enrollment, announced today it has launched its SYNERGY-AI Oncology Clinical Trial Command Center (OCTCC) with the mission to disrupt and accelerate the clinical trial enrollment process. 13, 2021 13:00 UTC.
Clinical trials for different kinds of drugs often mandate differences in the patient pools. Technologies such as bigdata and deep learning enable algorithms to understand and correlate patient-specific genetic markers to better assess potential participants.
In order to gain marketing approval from regulatory authorities for a novel therapeutic intervention, highly accurate and elaborate clinical trial data is required to validate the drug’s safety and effectiveness towards a specific target indication. Researchers collect data from people and compare changes throughout time.
International deep real-world evidence company Savana is on a mission to give health researchers the power to unlock the clinical value embedded within electronic health records (EHRs) using artificial intelligence (AI) and clinical Natural Language Processing (NLP) techniques.
Syntegra has also engaged with the Federal Drug Administration (FDA) to evaluate the role of synthetic data in regulatory decisions, for COVID-19 and beyond.
With the COVID-19 pandemic, there has never been a time when rapid, low burden access to patient-level data, at scale, was more urgent” says Michael D.
The clinical trials landscape is evolving more rapidly than ever before. Meanwhile, decentralisation and the BigData revolution are transforming the way researchers run clinical trials, and previously untapped geographies are emerging as new hubs for future research. of the global trial landscape.
We organize all of the trending information in your field so you don't have to. Join 21,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content